Skip to main content
OpenTrials
Completed

NCT Number: NCT00289588

An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection in Soldiers

The main purpose of this study is to determine if applying mupirocin into soldiers noses who are colonized with methicillin-resistant Staphylococcus aureus (MRSA) will reduce infections in them and their cohort of fellow soldiers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Community-Acquired MRSA Infections Abscess Abscesses Bacterial Infections Bacterial Infections and Mycoses Cellulitis Connective Tissue Diseases Folliculitis Gram-Positive Bacterial Infections Hair Diseases Infections Inflammation Pathologic Processes Pathological Conditions, Signs and Symptoms Skin Diseases Skin Diseases, Infectious Skin and Connective Tissue Diseases Staphylococcal Infections Suppuration

Age range

17 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Brooke Army Medical Center

Fort Sam Houston, Texas, 78234, United States

About this study

Community-acquired MRSA infections are increasingly common in the community and in particular among certain groups of which soldiers are one. Many researchers and clinicians have postulated that one method to prevent infections is to selectively eradicate CA-MRSA in those who are colonized with the pathogen. The two main purposes of the study are: to determine if selective CA-MRSA eradication in subjects reduces infections in the CA-MRSA colonized individual; and to determine if selective CA-MRSA eradication in subjects reduces infections in the study cohort. Other information concerning CA-MRSA includes: prevalence, risk factors, and virulence data. The population will be soldiers enrolled in the combat medic training class at Ft. Sam Houston. We will enroll approximately 3000 soldiers over a two year period. After informed written consent, we will culture their anterior nares nares and administer questionnaires at the beginning and at the end of the study, following them prospectively for infections. The follow-up period will be 16 weeks. For those with CA-MRSA in their nares, they will be randomized (by cohort) to receive either 5 days of mupirocin or placebo.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Soldiers enrolled into the combat medic course at Ft. Sam Houston, TX.

-

Exclusion criteria

Allergy to mupirocin.

-

Treatment and study plan

Mupirocin (drug)

Drug

Primary outcomes

  1. Soft tissue infections in subjects who received the study medication and soft tissue infections in the study cohorts.

Secondary outcomes

  1. Changes in S. aureus carriage rates (including MRSA).

Sponsors and collaborators

Lead sponsor

Brooke Army Medical Center

Fed

Collaborators

  • Becton, Dickinson and Company
  • GlaxoSmithKline

Registry information

Official study title

An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus Infection in Soldiers: a Controlled Trial

Important dates

Study start
2005
Study completion
2005
First posted
Feb 10, 2006
Registry last updated
Feb 16, 2006

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.